



PATENT
Atty. Dkt. No. NREL 01-36
SN 09/917,376

IN THE SPECIFICATION

In accordance with the revised format for amendments, the following replacement paragraphs are presented.

On page 26, line 31, the following replacement paragraph is presented:

The invention provides pharmaceutical compositions containing a substantially purified AviIII polypeptide of the invention and if necessary a pharmaceutically acceptable carrier. Such pharmaceutical compositions are administered to cells, tissues, or patients, for example, to aid in delivery or targeting of other pharmaceutical compositions. For example, AviIII polypeptides may be used where carbohydrate-mediated liposomal interactions are involved with target cells. Sihorkar, V. et al. (2001), *J. Pharmacy & Pharmaceutical Sciences* May-Aug 4(2): 138-58.

On page 28, lines 10-14, the following replacement paragraph is presented:

Therapeutic Applications

The AviIII polypeptides of the invention are effective in adding in delivery or targeting of other pharmaceutical compositions within a host. For example, AviIII polypeptides may be used where carbohydrate-mediated liposomal interactions are involved with target cells. Sihorkar, V. et al. (2001), *J. Pharm Pharm Sci.* May-Aug 4(2): 138-58.